© 2026 Optics and Photonics at Nottingham
43%
56.3%
8.8%
£5m+
Data for 2020-2025 from SciVal
Rahman, Ruman; Janowski, Miroslaw; Killick-Cole, Clare L; Singleton, William G B; Campbell, Emma; Walczak, Piotr; Khatua, Soumen; Faltings, Lukas; Symons, Marc; Schneider, Julia R; Kwan, Kevin; Boockvar, John A; Gill, Steven S; Oliveira, J Miguel; Beccaria, Kevin; Carpentier, Alexandre; Canney, Michael; Pearl, Monica; Veal, Gareth J; Meijer, Lisethe; Walker, David A
Childhood brain tumors: A review of strategies to translate CNS drug delivery to clinical trials Journal Article
In: Cancers (Basel), vol. 15, no. 3, pp. 857, 2023.
Abstract | Tags: blood-brain barrier, brain tumor model, childhood brain tumors, companion animal, Drug delivery, drug repurposing, preclinical, xenograft
@article{Rahman2023-fy,
title = {Childhood brain tumors: A review of strategies to translate
CNS drug delivery to clinical trials},
author = {Ruman Rahman and Miroslaw Janowski and Clare L Killick-Cole and William G B Singleton and Emma Campbell and Piotr Walczak and Soumen Khatua and Lukas Faltings and Marc Symons and Julia R Schneider and Kevin Kwan and John A Boockvar and Steven S Gill and J Miguel Oliveira and Kevin Beccaria and Alexandre Carpentier and Michael Canney and Monica Pearl and Gareth J Veal and Lisethe Meijer and David A Walker},
year = {2023},
date = {2023-01-01},
journal = {Cancers (Basel)},
volume = {15},
number = {3},
pages = {857},
publisher = {MDPI AG},
abstract = {Brain and spinal tumors affect 1 in 1000 people by 25 years of
age, and have diverse histological, biological, anatomical and
dissemination characteristics. A mortality of 30-40% means the
majority are cured, although two-thirds have life-long
disability, linked to accumulated brain injury that is acquired
prior to diagnosis, and after surgery or chemo-radiotherapy.
Only four drugs have been licensed globally for brain tumors in
40 years and only one for children. Most new cancer drugs in
clinical trials do not cross the blood-brain barrier (BBB).
Techniques to enhance brain tumor drug delivery are explored in
this review, and cover those that augment penetration of the
BBB, and those that bypass the BBB. Developing appropriate
delivery techniques could improve patient outcomes by ensuring
efficacious drug exposure to tumors (including those that are
drug-resistant), reducing systemic toxicities and targeting
leptomeningeal metastases. Together, this drug delivery strategy
seeks to enhance the efficacy of new drugs and enable
re-evaluation of existing drugs that might have previously
failed because of inadequate delivery. A literature review of
repurposed drugs is reported, and a range of preclinical brain
tumor models available for translational development are
explored.},
keywords = {blood-brain barrier, brain tumor model, childhood brain tumors, companion animal, Drug delivery, drug repurposing, preclinical, xenograft},
pubstate = {published},
tppubtype = {article}
}
A part of the University of Nottingham
© 2026 Optics and Photonics at Nottingham. Created for free using WordPress and Kubio